PharmaCorp Rx Inc. faces a challenging day on the TSXV with a notable drop in stock price.
In the latest trading session, PharmaCorp Rx Inc. (PCRX.V) saw a decline of 3.85%, closing at CA$0.50. This drop is concerning for investors, especially considering the company's recent financial performance and growth plans.
Investor takeaway: Investors should be cautious, as PharmaCorp's recent acquisition and revenue growth may not be enough to counter current market sentiments affecting its stock.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$100.28M
52W high
$0.58
52W low
$0.40
1W change
+2.00%
Beta
-4.27
Analyst Price Targets
Based on analyst covering PCRX
Wall Street analysts forecast PCRX stock price to rise 30.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+30.7% Upside
Current Price
C$0.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
70.6%
Annualized
90-Day Vol
61.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.61
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.54 | C$0.42 – C$0.69 |
| 60 trading days | C$0.57 | C$0.41 – C$0.81 |
| 90 trading days | C$0.61 | C$0.40 – C$0.93 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
PharmaCorp's stock drops 3.85% in a single trading day.
With a market cap of CA$88.78 million, PharmaCorp Rx Inc. continues to navigate a tough market landscape.
Bull case
PharmaCorp has reported strong revenue growth, with a 79.4% increase in Q1 2026 compared to last year. This suggests potential for long-term growth.
Bear case
Despite recent successes, today’s stock decline raises concerns about investor confidence, especially given the company’s negative profit margin and lack of dividends.
Market Reaction to Recent Developments
Even with an impressive 79.4% revenue growth reported in Q1 2026, today’s stock performance indicates that investors are being cautious. The recent acquisition of a pharmacy in Morrisburg, Ontario, while promising for future growth, may not have been enough to boost short-term confidence.
Understanding the Financial Landscape
PharmaCorp's current market cap is CA$88.78 million, with a profit margin of -0.0671. These figures highlight the challenges the company faces, particularly in a competitive market where profitability and investor confidence are key. The absence of a dividend yield further complicates the stock's appeal for income-focused investors.
Looking Ahead
Investors should watch for PharmaCorp's upcoming financial reports and strategic initiatives. While the recent drop in stock price is concerning, the company's growth trajectory could offer opportunities for those willing to take a long-term view. For more insights on PharmaCorp Rx Inc., visit our detailed analysis on PCRX.V.
Advertisement
